Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Audentes Therapeutics Stock Is Skyrocketing Today

By Brian Feroldi - Dec 3, 2019 at 2:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares more than doubled after the gene therapy company announced that it has accepted a buyout offer. Here are the key details.

What happened

Shares of Audentes Therapeutics ( BOLD ) are skyrocketing today, up by 105% as of 2:47 p.m. EST, after the clinical-stage gene therapy specialist announced it has agreed to be acquired.

So what

Astellas Pharma, a pharmaceutical company based in Japan, has agreed to purchase Audentes Therapeutics.

Here are the key terms of the deal:

  • The purchase price is $60 per share. That represents a total equity value of about $3 billion.
  • The offer represents a 110% premium over yesterday's closing price. 
  • This is an all-cash deal.
  • Both companies' boards have unanimously approved the transaction.
  • Audentes will operate as an independent subsidiary after the deal is completed.
Businessmen shaking hands and exchanging money

Image source: Getty Images.

Traders are bidding up the share price in response.

Now what

Audentes Therapeutics CEO Matthew Patterson stated: "We are very pleased to enter into this merger agreement with Astellas. With its focus on innovative science and a global network of research, development and commercialization resources, we believe that operating as part of the Astellas organization optimally positions us to advance our pipeline programs and serve our patients."

The odds of this deal going through look to be very high since both boards have unanimously approved the transaction. Audentes shareholders deserve to take a victory lap today and should start the search for another great healthcare stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Audentes Therapeutics, Inc. Stock Quote
Audentes Therapeutics, Inc.
BOLD

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.